Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

DNA data saved: 23andMe co-founder Anne Wojcicki has bid $305 million through a nonprofit to acquire her bankrupt company, ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...